WO2001092523A3 - Human polynucleotides and polypeptides encoded thereby - Google Patents

Human polynucleotides and polypeptides encoded thereby Download PDF

Info

Publication number
WO2001092523A3
WO2001092523A3 PCT/US2001/010836 US0110836W WO0192523A3 WO 2001092523 A3 WO2001092523 A3 WO 2001092523A3 US 0110836 W US0110836 W US 0110836W WO 0192523 A3 WO0192523 A3 WO 0192523A3
Authority
WO
WIPO (PCT)
Prior art keywords
orfx
polypeptides encoded
polynucleotide
polypeptide
human polynucleotides
Prior art date
Application number
PCT/US2001/010836
Other languages
French (fr)
Other versions
WO2001092523A2 (en
Inventor
Richard A Shimkets
Martin D Leach
Original Assignee
Curagen Corp
Richard A Shimkets
Martin D Leach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Richard A Shimkets, Martin D Leach filed Critical Curagen Corp
Priority to AU2001264557A priority Critical patent/AU2001264557A1/en
Publication of WO2001092523A2 publication Critical patent/WO2001092523A2/en
Publication of WO2001092523A3 publication Critical patent/WO2001092523A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention provides ORFX, a novel isolated polypeptide, as well as a polynucleotide encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
PCT/US2001/010836 2000-05-30 2001-05-29 Human polynucleotides and polypeptides encoded thereby WO2001092523A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001264557A AU2001264557A1 (en) 2000-05-30 2001-05-29 Human polynucleotides and polypeptides encoded thereby

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20313200P 2000-05-30 2000-05-30
US60/206,132 2000-05-30
US22871600P 2000-08-29 2000-08-29
US60/228,716 2000-08-29

Publications (2)

Publication Number Publication Date
WO2001092523A2 WO2001092523A2 (en) 2001-12-06
WO2001092523A3 true WO2001092523A3 (en) 2002-09-06

Family

ID=26898338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010836 WO2001092523A2 (en) 2000-05-30 2001-05-29 Human polynucleotides and polypeptides encoded thereby

Country Status (1)

Country Link
WO (1) WO2001092523A2 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010217A2 (en) 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
US7258855B2 (en) 2000-09-19 2007-08-21 Kyowa Hakko Kogyo Co., Ltd. Polypeptides having phospholipase A2 activity
AU2001290242A1 (en) 2000-09-22 2002-04-02 Kyowa Hakko Kogyo Co., Ltd. Beta-catenin nuclear localized protein
EP1414477B1 (en) * 2001-04-17 2015-06-10 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic interventions
WO2003012121A2 (en) 2001-07-31 2003-02-13 The General Hospital Corporation Collagen xxii, a novel human collagen and uses thereof
DE10224338A1 (en) * 2002-05-29 2003-12-24 Gerald-F Gerlach Means and methods for the enrichment and detection of microorganisms
AU2003272946A1 (en) * 2002-10-09 2004-05-04 Takeda Pharmaceutical Company Limited Novel protein and dna thereof
WO2005041882A2 (en) * 2003-10-31 2005-05-12 The Burnham Institute Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
WO2005087929A1 (en) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
AR050866A1 (en) 2004-09-09 2006-11-29 Dow Agrosciences Llc INOSITOL GENES 2-KINASE POLYPHOSPHATE AND USES OF THE SAME
GB0522113D0 (en) * 2005-10-28 2005-12-07 Ares Trading Sa vWFA-domain containing proteins
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
CN101801402B (en) * 2007-07-06 2013-08-28 乌得勒支大学控股有限公司 Treatment and prevention of inflammatory diseases and autoimmune diseases
US8367801B2 (en) * 2008-01-10 2013-02-05 Endocrine Pharmaceuticals Limited Proteinaceous compounds
SG11201401043SA (en) 2011-09-09 2014-08-28 Agency Science Tech & Res P53 activating peptides
EP3384938A1 (en) * 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
DE102013009654A1 (en) * 2013-06-07 2014-12-11 Klaus Olek A method for the detection and differentiation of body fluids from forensic material
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP2018513166A (en) * 2015-04-20 2018-05-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Specific peptide binders for proteins identified through systematic exploration, maturation and elongation processes
KR101669140B1 (en) 2015-04-28 2016-10-26 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
KR102622462B1 (en) * 2016-01-18 2024-01-08 주식회사 엘지생활건강 Peptide for accelerating delivery to nerve cells
WO2019104244A1 (en) * 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
CN109258625A (en) * 2018-10-14 2019-01-25 青海大学 It is a kind of for improve yak frozen semen freeze after quality dilution formula of liquid
WO2022104267A1 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053051A2 (en) * 1998-04-09 1999-10-21 Genset 5' ests and encoded human proteins
WO1999063077A2 (en) * 1998-06-04 1999-12-09 Tm Technologies, Inc. Compositions of nucleic acid which alter ligand-binding characteristics and related methods and products
WO2000018912A2 (en) * 1998-09-25 2000-04-06 Bayer Aktiengesellschaft Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053051A2 (en) * 1998-04-09 1999-10-21 Genset 5' ests and encoded human proteins
WO1999063077A2 (en) * 1998-06-04 1999-12-09 Tm Technologies, Inc. Compositions of nucleic acid which alter ligand-binding characteristics and related methods and products
WO2000018912A2 (en) * 1998-09-25 2000-04-06 Bayer Aktiengesellschaft Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 3 May 2000 (2000-05-03), SKUCE C.: "Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone RP11-611D20", XP002190197 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8394843B2 (en) 2006-05-31 2013-03-12 Takeda California, Inc. Substituted isoindoles as glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Also Published As

Publication number Publication date
WO2001092523A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
WO2001092523A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001090366A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2001036645A3 (en) Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
WO2001049729A3 (en) Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
WO2002066647A3 (en) Type 2 ctokine receptor and nucleic acids encoding same
WO2001074856A3 (en) Wnt-7b-like polypeptides and nucleic acids encoding same
WO2001070978A3 (en) Polypeptides and nucleic acids encoding same
WO2001062928A3 (en) Polypeptides and nucleic acids encoding same
WO2002002625A3 (en) Novel fibroblast growth factors and nucleic acids encoding same
WO2001061009A3 (en) Polypeptides and nucleic acids encoding same
WO2003025147A3 (en) Novel polynucleotides and proteins encoded thereby
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
WO2001044473A3 (en) Polypeptides and nucleic acids encoding same
WO2001036638A3 (en) Polypeptides and nucleic acids encoding same
WO2001085767A3 (en) Human proteins polynucleotides encoding them and methods of using the same
WO2000070046A3 (en) Secreted polypeptides and corresponding polynucleotides
WO2001068851A3 (en) Polypeptides and nucleic acids encoding same
WO2001023561A3 (en) Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats
WO2001023572A3 (en) Polynucleotides and polypeptides encoded thereby
WO2000075321A3 (en) Polynucleotides and membrane-bound polypeptide encoded thereby
WO2003040345A3 (en) Type 2 cytokine receptor and nucleic acids encoding same
WO2001032874A3 (en) Polypeptides and nucleic acids encoding same
WO2001058946A3 (en) Polynucleotides and polypeptides encoded thereby

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)